Furthermore, empagliflozin-mediated improvements in endothelium-dependent vasodilation have been noted in a co-morbid rheumatoid arthritis/T2DM rat model, Zucker diabetic fatty rats, metabolic syndrome ZSF1 rats, and in STZ-treated apolipoprotein-E (apoE)-deficient mice [63,64,65,66]. This evidence concerns the gene APOE and metabolic syndrome.